Current status of local penile therapy

International Journal of Impotence Research

Volumn 14, Issue , 2002, Pages S70-S81

  Montorsi, Francesco ^a   Salonia, A ^a   Zanoni, M ^a   Pompa, P ^a   Cestari, A ^a   Guazzoni, G ^a   Barbieri, L ^a   Rigatti, P ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Alprostadil; Erectile dysfunction; Local penile therapy; Topical therapy

Indexed keywords

ADMINISTRATION, TOPICAL; HUMANS; IMPOTENCE; INJECTIONS; MALE; VASODILATOR AGENTS;

AMINOPHYLLINE; APOMORPHINE; ATROPINE; CALCITONIN GENE RELATED PEPTIDE; DIHYDROERGOTOXINE; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; LINSIDOMINE; MINOXIDIL; MOXISYLYTE; NITROPRUSSIDE SODIUM; PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; PROSTAVASIN; SILDENAFIL; VASOACTIVE AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE;

CLINICAL TRIAL; CONFERENCE PAPER; CORPUS CAVERNOSUM; DEVICE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; ERECTILE DYSFUNCTION; FIBROSIS; HEMATOMA; HUMAN; INFECTION; MALE; ORTHOSTATIC HYPOTENSION; PAIN; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIAPISM; PRIORITY JOURNAL; SKIN; TACHYCARDIA; TUNICA ALBUGINEA; URETHRA INJURY;

EID: 0036200037     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900808     Document Type: Article

References (80)

1. Efficacy and safety of six dose and dose optimization regimen of sublingual apomorphine versus placebo in men with erectile dysfunction: The Apomorphine Study Group
2. Pharmacological management of erectile dysfunction
3. Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction
4. Effectiveness and safety of multidrug intracavernous therapy for vasculogenic impotence
5. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence
6. Intracavernous vasoactive pharmacotherapy: The impact of a new self-injection device
7. Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine
8. 1 in erectile dysfunction
9. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction
10. Intracavernosal injection and intraurethral therapy for erectile dysfunction
11. Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs
12. Improved hemodynamic response after long-term intracavernous injection for impotence
13. 1 therapy modify the intracavernous musculature?
14. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment
15. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy
16. Modulation of noradrenaline-induced membrane currents by papaverine in rabbit vascular smooth muscle cells
17. Pharmacology of drugs used for treatment of erectile dysfunction and priapism
18. 1 with other intracavernous injections
19. 1 in erectile failure: A survey of world-wide experience
20. Effect of phentolamine on venous return in human erection
21. The efficacy and acceptance of intracavernous autoinjection therapy with the combination of papaverine/phentolamine: A prospective multicenter trial in 60 patients
22. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction
23. 1 plus procaine in the treatment of erectile dysfunction
24. Efficacy and safety of intracavernosal Alprostadil in men with erectile dysfunction
25. Penile fibrosis during 18 months of intracavernosal therapy with Alprostadil (Caverject™)
26. 1) in erectile dysfunction (ED)
27. Intracavernous alprostadil alfadex - An effective and well tolerated treatment for erectile dysfunction: Results of a long-term European study
28. Quality of life effects of alprostadil therapy for erectile dysfunction
29. Effect of moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue
30. Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: A dose-finding study versus placebo
31. Efficacy and tolerability of moxisylyte and placebo injected intracavernously in patients with erectile dysfunction (ED): A multicenter, double-blind study
32. Vasoactive intestinal polypeptide and phentolamine mesylate administered by auto-injector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents
33. The results of a 6 month multi-center placebo-controlled study of Invicorp™ in the treatment of nonpsychogenic erectile dysfunction
34. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: A multicentre double-blind placebo-controlled study
35. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction
36. 1: Possible alternative to penile implants in selected patients
37. Calcitonin gene-related peptide: A possible role in human penile erection and its therapeutical application in impotent patients
38. Preliminary results with the nitric oxide donor linsidomine chloridrate in the treatment of human erectile dysfunction
39. 1 and the nitric oxide donor linsidomine for erectile failure: A diagnostic comparative study of 40 patients
40. Effect of nitric oxide-donor, linsidomine chloridrate, in treatment of human erectile dysfunction caused by venous leakage
41. 1 in patients with erectile dysfunction
42. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-Year experience with 615 cases
43. Atropine role in the pharmacological erection test: Study of 228 patients
44. Experience with triple-drug therapy in a pharmacological erection program
45. Intracavernous self-injection pharmacotherapy program: Analysis of results and complications
46. 1 injection to oral sildenafil citrate in patients with erectile dysfunction: Results of a multi-center European study: The Sildenafil Multicenter Study Group
47. Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 y
48. Intracavernous Alprostadil Alfadex is effective and safe in patients with erectile dysfunction after failing sildenafil
49. Treatment of intracorporeal injection non-response with sildenafil alone or in combination with triple agent intracorporeal injection therapy
50. Functional and radiologic evidence of vascular communication between the spongiosal and cavernosal compartments of the penis
51. Treatment of men with erectile dysfunction with transurethral alprostadil
52. Review of intraurethral suppositories and iontophoresis therapy for erectile dysfunction
53. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction
54. Optimizing the therapeutic approach of transurethral alprostadil
55. Intraurethral alprostadil for treatment of erectile dysfunction in patients with spinal cord injury
56. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy
57. Use of transurethral alprostadil (MUSE) for glans tumescence in a patient with penile prosthesis
58. Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis
59. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners
60. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting
61. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy
62. Results from different patient populations using combined therapy with alprostadil and sildenafil: Predictors of satisfaction
63. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional ACTIS: A comparative, randomised, crossover, multicenter study
64. Transurethral alprostadil with MUSE™ vs intracavernous alprostadil - A comparative study in 103 patients with erectile dysfunction
65. Intracavernosal versus intraurethral alprostadil: A prospective randomised study
66. MUSE therapy: Preliminary clinical observations
67. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy
68. Topical nitrate treatment of impotence
69. Topical nitroglycerin: A potential treatment for impotence
70. Topical treatment of erectile dysfunction: Randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate
71. Topical vasoactive cream in the treatment of erectile failure: A prospective, randomised placebo-controlled trial
72. Minoxidil versus nitroglycerin: A prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence
73. Topical minoxidil in the treatment of male erectile dysfunction
74. Prospective comparison of topical minoxidil to vacuum constriction device and intracorporeal papaverine injection in treatment of erectile dysfunction due to spinal cord injury
75. Papaverine topical gel for treatment of erectile dysfunction
76. 1 SEPA gel for the treatment of erectile dysfunction
77. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: Long-term dropout parameters
78. The causes of patient dropout from penile self injection therapy for impotence
79. Reasons of dropout from short- and long-term self-injection therapy for impotence